Recursion Pharmaceuticals Inc (NASDAQ:RXRX) finished Wednesday with an addition of $0.21 to close at $7.78, an upside of 2.77 percent. An average of 2,540,520 shares of common stock have been traded in the last five days. There was a fall of -$0.35 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 4,032,995 shares traded, while the 50-day average volume stands at 5,118,668.
RXRX stock has decreased by -9.64% in the last month. The company shares reached their 1-month lowest point of $7.54 on 09/26/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $4.54 and a high of $16.75 in 52 weeks. It has reached a new high 14 times so far this year and achieved 0.91% or $0.07 in price. In spite of this, the price is down -53.54% from the 52-week high.
Insider Transactions
RXRX stock investors should be aware that Recursion Pharmaceuticals Inc (RXRX) stock had its last reported insider trading activity 9 days ago on Sep 19. In this transaction, the insider spent $74,278. Chief Business Officer, Virani Shafique, disposed of 18,000 shares at a price of $8.66 on Sep 15. The insider now owns more than $155,880 worth of shares. Prior to that, Chief Financial Officer Secora Michael went on to Sale 25,000 shares at $8.69 each on Sep 13. An amount of $217,318 was transacted.
Valuation Metrics
Recursion Pharmaceuticals Inc (RXRX) stock’s beta is 0.04. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 32.94, the price-to-book (PB) ratio at 3.36.
Financial Health
The quick ratio of Recursion Pharmaceuticals Inc for the three months ended June 29 was 3.72, and the current ratio was 3.72, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.10 and a total debt to equity ratio of 0.11 for the quarter ending June 29. Recursion Pharmaceuticals Inc’s EBITDA margin for the year ending June 29 is -567.83%, while its operating margin for the same period stands at -550.41%. Its gross profit as reported stood at -$8.43 million compared to revenue of $39.84 million.
Earnings Surprise
For the three-month period that ended June 29, Recursion Pharmaceuticals Inc had $1.16 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$76.73 million in the quarter, while revenues of -$65.33 million were grew 14.56%. The analyst consensus anticipated Recursion Pharmaceuticals Inc’s latest quarter earnings to come in at -$0.37 per share, but it turned out to be -$0.38, a -2.70% surprise. For the quarter, EBITDA amounted to -$76.17 million. Shareholders own equity worth $215.59 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Recursion Pharmaceuticals Inc (RXRX) price momentum. RSI 9-day as of the close on 27 September was 35.18%, suggesting the stock is Neutral, with historical volatility in this time frame at 32.55%.
As of today, RXRX’s price is $7.79 -4.31% or -$0.35 from its 5-day moving average. RXRX is currently trading -8.79% lower than its 20-day SMA and +51.36% higher than its 100-day SMA. However, the stock’s current price level is -42.92% below the SMA50 and -16.70% below the SMA200.
The stochastic %K and %D were 8.64% and 7.79%, respectively, and the average true range (ATR) was 0.44. With the 14-day stochastic at 17.71% and the average true range at 0.53, the RSI (14) stands at 37.51%. The stock has reached -0.41 on the 9-day MACD Oscillator while the 14-day reading was at -0.53.
Analyst Ratings
Morgan Stanley launched coverage on Recursion Pharmaceuticals Inc (NASDAQ: RXRX) in its analyst report released on May 22, 2023. The firm assigned the stock an Equal-weight rating.
